Premium
Clear cell hidradenoma of the skin—a third tumor type with a t(11;19)‐associated TORC1 – MAML2 gene fusion
Author(s) -
Behboudi Afrouz,
Winnes Marta,
Gorunova Ludmila,
van den Oord Joost J.,
Mertens Fredrik,
Enlund Fredrik,
Stenman Göran
Publication year - 2005
Publication title -
genes, chromosomes and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.754
H-Index - 119
eISSN - 1098-2264
pISSN - 1045-2257
DOI - 10.1002/gcc.20168
Subject(s) - hidradenoma , fusion gene , mucoepidermoid carcinoma , exon , gene , biology , chromosomal translocation , cancer research , microbiology and biotechnology , carcinoma , genetics
Recent studies have shown that the t(11;19)(q21;p13) translocation in mucoepidermoid carcinomas and benign Warthin's tumors results in a fusion of the N‐terminal CREB‐binding domain of the cAMP coactivator TORC1 (a.k.a. MECT1 and WAMTP1) to the Notch coactivator MAML2. Here we show that a third tumor type, clear cell hidradenoma of the skin, also expresses this gene fusion. RT‐PCR analysis of a clear cell hidradenoma with a t(11;19)(q21;p13) translocation revealed expression of a TORC1 – MAML2 fusion transcript consisting of exon 1 of TORC1 fused to exons 2–5 of MAML2 . Because the fusion was only detected in a single case, the frequency of this aberration in clear cell hidradenomas remains unknown. These results demonstrate that the t(11;19) in mucoepidermoid carcinoma, Warthin's tumor, and clear cell hidradenoma targets the same genes and results in identical gene fusions, indicating that at least subgroups of these glandular tumors evolve through activation of the same molecular pathways. © 2005 Wiley‐Liss, Inc.